MedTrace Logo

Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research (EISNER)

NCT00927693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2137

Last updated 2011-09-29

No results posted yet for this study

Summary

Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research (EISNER) is a multi-study research program being conducted at Cedars-Sinai Medical Center.

The principal objective of this randomized trial (referred to as "Study 1") is to assess whether coronary artery calcium (CAC) scanning provides clinical benefit thus improving patient outcomes in asymptomatic subjects with intermediate coronary artery disease (CAD) risk. Additionally, the study is designed to assess the value of combining the CAC scan with the Framingham risk score (FRS) and measurements of serum or plasma biomarkers to predict outcomes.

Conditions

Interventions

OTHER

Coronary Artery Calcium (CAC) Scan

A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.

Sponsors & Collaborators

  • The Eisner Foundation

    collaborator UNKNOWN

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Daniel S. Berman, M.D. · Cedars-Sinai Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Primary Completion
2009-07-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00927693 on ClinicalTrials.gov